Key Highlights

  • Novo Nordisk shares are trading at $38.30 in Wednesday's session, down 2.80%.
  • The stock is extending its slide following Monday's underwhelming 2030 strategy update, including a pipeline sales target of DKK150 billion by 2035.
  • A research firm downgraded the stock to Underweight, citing continued market-share loss to Eli Lilly in obesity and diabetes.
  • The decline comes despite positive CagriSema Phase 3 data and incremental news including a Singapore regulatory approval for Wegovy in liver disease.

Shares Extend Post-Strategy-Day Slide Toward 52-Week Lows

Novo Nordisk (NYSE:NVO) shares are falling further in Wednesday's session as investors continue to digest the company's underwhelming 2030 strategy update from earlier this week. The stock remains under pressure following management's pipeline sales guidance of DKK150 billion by 2035 and Revenue growth targets in line with peers, both of which were seen as too modest by much of the market. That reaction was compounded this week by a downgrade to Underweight from a major research firm, which cited continued market-share loss to Eli Lilly (NYSE:LLY) in both obesity and diabetes.

Positive Trial Data Not Enough to Offset Broader Concerns

The decline comes despite a string of incremental positive developments, including Phase 3 CagriSema data showing superior weight loss versus tirzepatide, a Singapore regulatory approval for Wegovy in liver disease, and reports that the company is diversifying into hair-loss treatments. None of that news flow has been enough to overcome broader investor concerns about semaglutide's looming Patent expiry and Lilly's widening lead in the obesity-market race, leaving shares down nearly 3% and near 52-week lows.

A Global Leader Facing a Pivotal Stretch

Novo Nordisk is a Danish global healthcare company specializing in the discovery, development, Manufacturing and Marketing of pharmaceutical products for chronic diseases, operating through two core segments: Diabetes and Obesity Care, and Rare Disease. Its portfolio is dominated by blockbuster GLP-1 therapies such as Ozempic, Wegovy and Rybelsus, alongside a broad range of insulin products, hemophilia treatments and growth hormone therapies. With over 68,000 employees, the company remains one of the world's leading and most valuable pharmaceutical companies even as it works to reassure investors about its long-term competitive position.